CD8A and neoplasm: The main finding of our research is that CL7, a CD300c antibody, and anti-PD-1 synergistically increased the M1/M2 ratio and activated CD8+ T cells and NK cells in the TNBC tumor microenvironment (TME), leading to a reduction in tumor volume.